Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Current Deferred Revenue of $11.9 million in Q4 2025, up 169357.14% on a QoQ basis from $7000.0 in Q3 2025, and down 3.25% YoY from $12.3 million in Q4 2024.
Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Current Deferred Revenue for 5 consecutive years, with $11.9 million the latest figure, recorded in Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $11.9 million, down 3.25% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.9 million (down 3.25% YoY), and the FY2025 annual result was $11.9 million, down 3.25% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $11.9 million, up from $7000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $16.2 million in Q1 2022, with the low at $7000.0 in Q3 2025.
- A 5-year average of $7.9 million and a median of $11.7 million in 2021 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 1361.18% in 2025, down 99.94% in 2025.
- Lyra Therapeutics' Current Deferred Revenue stood at $11.7 million in 2021, then plunged by 89.12% to $1.3 million in 2022, then jumped by 30.04% to $1.7 million in 2023, then surged by 639.45% to $12.3 million in 2024, then declined by 3.25% to $11.9 million in 2025.
- The last three Current Deferred Revenue figures came in at $11.9 million (Q4 2025), $7000.0 (Q3 2025), and $11.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.86 Mn |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 11.89 Mn |
| Mar 31, 2025 | 12.08 Mn |
| Dec 31, 2024 | 12.26 Mn |
| Sep 30, 2024 | 12.47 Mn |
| Jun 30, 2024 | 814,000.00 |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 14.48 Mn |
| Mar 31, 2023 | 14.94 Mn |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 2.73 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 16.25 Mn |
| Dec 31, 2021 | 11.72 Mn |
| Sep 30, 2021 | 8.30 Mn |
| Jun 30, 2021 | 12.00 Mn |